HEDIS® Tip Sheet

Non-Recommended PSA-Based Screening in Older Men (PSA)

Measure Description

The percentage of men 70 years and older who were screened unnecessarily for prostate cancer using prostate-specific antigen (PSA)-based screening.

Note: A lower rate indicates better performance.

Product Line: Medicare

Codes Included in the Current HEDIS® Measure

Description	Code
PSA Lab Test	**CPT**: 84152, 84153, 84154 **HCPCS**: G0103
PSA Lab Test Exclusion	**CPT**: 84153 **HCPCS**: G0103
Prostate Cancer	**ICD-10**: C61, D07.5, D40.0, Z15.03, Z85.46
Prostate Dysplasia	**ICD-10**: N42.30, N42.31, N42.32, N42.39

Medications

Description	Prescription
5-alpha Reductase Inhibitors	Finasteride, Dutasteride

Ways Providers can Improve HEDIS® Performance

- Avoid testing for low-risk men if patient:
  - Have no prior family history of prostate cancer.
  - Have no prior history of elevated PSA test value (>4.0 nanogram/milliliter [ng/mL]).
- In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms based on family history, race/ethnicity, comorbid.
- Utilize USPSTF guidance on PSA screening.

Ways Health Plans can Improve HEDIS® Performance

- Educate members on the adverse effects and benefits of the testing.
- Utilize culturally and linguistically competent language when discussion testing with members.
- Audit, identify, and educate providers who unnecessarily conduct PSA screening on the risks of testing.

Required Exclusions

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.
- Men who had a diagnosis for which PSA-based testing is clinically appropriate. Any of the following meet criteria:

Senior Whole Health
BY MOLINA HEALTHCARE

- Prostate cancer diagnosis any time during the member's history through December 31 of the measurement year. Do not include laboratory claims (POS: 81).
- Dysplasia of the prostate any time during the measurement year or the year prior to the measurement year. Do not include laboratory claims (POS: 81).
- A PSA test during the year prior to the measurement year, where laboratory data indicate an elevated result (>4.0 nanograms/milliliter [ng/mL]).
- An abnormal PSA test result or finding during the year prior to the measurement year.
- Dispensed prescription for a 5-alpha reductase inhibitor during the measurement year.

All summaries of the measures contained herein are reproduced with permission from HEDIS® Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA).

The information presented herein is for informational and illustrative purposes only. It is not intended, nor is it to be used, to define a standard of care or otherwise substitute for informed medical evaluation, diagnosis and treatment which can be performed by a qualified medical professional. Molina Healthcare, Inc. does not warrant or represent that the information contained herein is accurate or free from defects.

COPYRIGHT NOTICE AND DISCLAIMER